These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 20068070)

  • 1. FOXM1 confers acquired cisplatin resistance in breast cancer cells.
    Kwok JM; Peck B; Monteiro LJ; Schwenen HD; Millour J; Coombes RC; Myatt SS; Lam EW
    Mol Cancer Res; 2010 Jan; 8(1):24-34. PubMed ID: 20068070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
    Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
    Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.
    McGovern UB; Francis RE; Peck B; Guest SK; Wang J; Myatt SS; Krol J; Kwok JM; Polychronis A; Coombes RC; Lam EW
    Mol Cancer Ther; 2009 Mar; 8(3):582-91. PubMed ID: 19276163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance.
    Karunarathna U; Kongsema M; Zona S; Gong C; Cabrera E; Gomes AR; Man EP; Khongkow P; Tsang JW; Khoo US; Medema RH; Freire R; Lam EW
    Oncogene; 2016 Mar; 35(11):1433-44. PubMed ID: 26148240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.
    Khongkow P; Karunarathna U; Khongkow M; Gong C; Gomes AR; Yagüe E; Monteiro LJ; Kongsema M; Zona S; Man EP; Tsang JW; Coombes RC; Wu KJ; Khoo US; Medema RH; Freire R; Lam EW
    Oncogene; 2014 Aug; 33(32):4144-55. PubMed ID: 24141789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.
    Millour J; de Olano N; Horimoto Y; Monteiro LJ; Langer JK; Aligue R; Hajji N; Lam EW
    Mol Cancer Ther; 2011 Jun; 10(6):1046-58. PubMed ID: 21518729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
    Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
    Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
    Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
    Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    Westhoff GL; Chen Y; Teng NNH
    Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes.
    Tan Y; Raychaudhuri P; Costa RH
    Mol Cell Biol; 2007 Feb; 27(3):1007-16. PubMed ID: 17101782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.
    Monteiro LJ; Khongkow P; Kongsema M; Morris JR; Man C; Weekes D; Koo CY; Gomes AR; Pinto PH; Varghese V; Kenny LM; Charles Coombes R; Freire R; Medema RH; Lam EW
    Oncogene; 2013 Sep; 32(39):4634-45. PubMed ID: 23108394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
    Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.
    Khongkow P; Gomes AR; Gong C; Man EP; Tsang JW; Zhao F; Monteiro LJ; Coombes RC; Medema RH; Khoo US; Lam EW
    Oncogene; 2016 Feb; 35(8):990-1002. PubMed ID: 25961928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance.
    Nestal de Moraes G; Delbue D; Silva KL; Robaina MC; Khongkow P; Gomes AR; Zona S; Crocamo S; Mencalha AL; Magalhães LM; Lam EW; Maia RC
    Cell Signal; 2015 Dec; 27(12):2496-505. PubMed ID: 26404623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    Westhoff GL; Chen Y; Teng NNH
    Int J Gynecol Cancer; 2017 Jun; 27(5):887-894. PubMed ID: 28498253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of the FoxM1 enhances the sensitivity of gastric cancer cells to cisplatin by targeting Mcl-1.
    Li X; Liang J; Liu YX; Wang Y; Yang XH; Bao-Hongluan ; Zhang GL; Du J; Wu XH
    Pharmazie; 2016 Jun; 71(6):345-8. PubMed ID: 27455555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer.
    Zhou J; Wang Y; Wang Y; Yin X; He Y; Chen L; Wang W; Liu T; Di W
    PLoS One; 2014; 9(5):e96989. PubMed ID: 24824601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin.
    Li X; Yao R; Yue L; Qiu W; Qi W; Liu S; Yao Y; Liang J
    J Cell Mol Med; 2014 May; 18(5):811-23. PubMed ID: 24628949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
    Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
    Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.